Brexit and life sciences: uncertainty reigns but change is on the way

One potential outcome of the British vote to leave the EU is the divergence of regulatory frameworks for bringing pharmaceutical products to market in the UK and the EU—UK IP rights may split from harmonised EU systems of protection.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

‘Don’t stifle UK AI innovation’: King's speech on AI Act prompts warnings

Sanofi and Regeneron triumph in UPC decision against Amgen

Novo Nordisk’s uphill battle in the counterfeit weight loss craze

Most active firms at UPC revealed in report on court’s first year

Brexit and life sciences: uncertainty reigns but change is on the way

Editor's picks

Editor's picks

More features